Oral Solid Dosage Contract Manufacturing Market Report Scope & Overview:

The oral solid dosage contract manufacturing market size was valued at USD 38.12 billion in 2025E and is expected to reach USD 60.23 billion by 2033, growing at a CAGR of 5.92% over the forecast period of 2026-2033. 

The global oral solid dosage contract manufacturing market is a precedent for the demand for stringent regulatory compliance. By complying with global manufacturers expose themselves to various international markets and make sure that their products are safe and of high quality. It fosters credibility with healthcare professionals and investors, builds a reputation, and facilitates strategic global expansion.

Oral Solid Dosage Contract Manufacturing Market Size and Forecast:

• Market Size in 2025E: USD 38.12 Billion

• Market Size by 2033: USD 60.23 Billion

• CAGR: 5.92% from 2026 to 2033

• Base Year: 2025E

• Forecast Period: 2026–2033

• Historical Data: 2022–2024

The U.S. Oral Solid Dosage Contract Manufacturing Market was valued at USD 9.59 billion in 2025E and is expected to reach USD 14.90 billion by 2033, growing at a CAGR of 5.70% over 2026-2033.  

The U.S. oral solid dose contract manufacturing is dominated by established pharmaceutical companies that invest heavily in infrastructure, automation and adherence to a regulatory market. Their involvement also contributes to skill transfer to the local workforce and supports the ongoing development of the supply chain. These companies support the excellence of the quality, the efficiency of the production process, the innovation. This dynamic has enabled the US to become world’s largest production of OSD & global hub with the highest oral solid dosage contract manufacturing market share.

For instance, in January 2025, Major pharmaceutical companies invested over USD 4.2 billion in U.S. OSD manufacturing facilities in 2024 to expand capacity, automation, and regulatory-compliant infrastructure.

Oral Solid Dosage Contract Manufacturing Market Drivers:

• Advancements in Drug Delivery Technologies, Driving the Oral Solid Dosage Contract Manufacturing Market Growth

Innovations in drug delivery systems play a critical role in the oral solid dosage contract manufacturing market. Advances, including sustained release, targeted release, and 3D printing, can improve the drug’s efficacy, the patient’s compliance, and the efficiency of the manufacturing process. These novel devices make elaborate preparations possible, limit adverse effects, and are designed for individualized therapies, particularly for chronic and oncology medications. When combined with regulatory assistance and more demand for specialized products, they can fuel the growth in outsourcing. Therefore, the oral solid dosage contract manufacturing market share sector is still growing, both in regulated and in emerging territories.

For instance, in June 2025, Controlled-release and targeted oral dosage forms made up over 38% of new global outsourcing contracts, reflecting rising demand for advanced OSD technologies in 2025.

Oral Solid Dosage Contract Manufacturing Market Restraints:

• Technological Barriers are Restraining the Oral Solid Dosage Contract Manufacturing Market 

Technological challenges in scaling up complex formulations are hindering the growth of the oral solid dosage contract manufacturing market. The challenges are related to process variation, automation, infrastructure (ageing), and skills shortage. The fact that drug development is capital-intensive and the complex regulatory landscape also impede rapid scale-up. These challenges hinder production uniformity, increase time-to-market, and raise operational costs – all of which hinder growth and affect the oral solid dosage contract manufacturing market share, especially for small and medium-sized CDMOs producing complex formulations.

For instance, in March 2025, only 28% of global OSD contract manufacturing facilities had fully automated systems, limiting scalability, consistency, and efficiency in producing complex formulations.

Oral Solid Dosage Contract Manufacturing Market Segmentation Analysis:

By Product 

Tablets were the dominant segment in the Oral Solid Dosage Contract Manufacturing Market analysis, with a 55.70% market share in 2025, owing to their low cost, simple administration, long shelf life, and good patient adherence. They are mainly used for chronic conditions, are thus well suited for high-volume outsourcing. It also exists in different formulations, including immediate, controlled, and delayed release, which increases demand for tablets. Accordingly, they have the most significant oral solid dosage contract manufacturing market share, especially in generics and global-scale production contracts.

The Capsules are emerging as the fastest growing segment in the global oral solid dosage contract manufacturing market trend, with a CAGR of 6.26, driven by due to their versatility, ease of swallowing, and ability to encapsulate complex or multi-part formulations. They are ideal for nutraceuticals, combination drugs, and moisture-sensitive APIs. The rising demand for gelatin-free and plant-based capsules also supports growth. These advantages, combined with expanding use in personalized medicine, significantly contribute to the overall oral solid dosage contract manufacturing market growth across therapeutic and consumer health sectors.Top of Form

By Mechanism

In 2025, the controlled release, controlled Oral Solid Dosage Contract Manufacturing Market had with 58.84% market share, as it can keep steady drug concentration over a prolonged time and help to achieve better treatment effects and patient compliance. It's cheaper and, because it requires fewer doses, has fewer side effects and is the favored treatment for chronic diseases, including hypertension, diabetes, and neurological diseases. With more pharmaceutical companies moving towards more sophisticated formulations, the need for controlled release technologies is increasing, and thus, the high-value oral solid dose contract manufacturing market.

The immediate release is the fastest-growing segment in the global Oral Solid Dosage Contract Manufacturing Market trend, owing to its fast-acting, low-cost, and broad application to acute and chronic diseases. It is commonly found in generics and over-the-counter medications, so that it can be produced at high volume. Increased global need for low-cost, quick-acting drugs, especially in developing countries, is helping to force growth for this segment, thereby driving the overall oral solid dosage contract manufacturing market share.

By End Use

The large-sized companies control the global Oral Solid Dosage Contract Manufacturing industry with a significant market share of 58.80%, owing to their mature infrastructure, regulatory compliance, and global manufacturing capability. These firms, which include Catalent and Thermo Fisher, are the types of preferred partners for big pharma that can manage complex formulas, high production levels, and international distribution. Their rigid quality systems and strong innovation make them gain the maximum oral solid dosage contract manufacturing market share, especially in regulated markets including the U.S. and Europe.

In the global oral solid dosage contract manufacturing industry, the Medium & Small Size Companies segment plays a vital role, registering the fastest growth over the forecast period, fueled by their ease of control, cost effectiveness, and filling niches for pharmaceuticals at either the regional or specialty levels. They also provide faster turnaround, personalized services, and have begun to leverage the latest technology to be more competitive for larger firms. Their flexibility to manage low-to-mid volume, specialised formulations is of interest to emerging pharma and generics. The increasing demand is also driving the oral solid dosage contract manufacturing market growth, particularly in Asia-Pacific and Latin America.

Oral Solid Dosage Contract Manufacturing Market Regional Analysis:

North America Leads the Global Oral Solid Dosage Contract Manufacturing Market in 2025

In 2025, the North American region dominated the global oral solid dosage contract manufacturing industry and accounted for 32.50% of the overall revenue share. owing to its highly concentrated presence of large pharmaceutical companies, sophisticated manufacturing setup, and stringent drug regulatory regime (FDA). Add to that high demand for generic and branded OSDs, as well as solid R&D work in the space, and leading CDMOs, including Catalent and Thermo Fisher, in the region. All of these factors are driving the market in North America holds the largest oral solid dosage contract manufacturing market share, especially for high-value & complex formulations.

Europe Strengthens Its Position in the Oral Solid Dosage Contract Manufacturing Market

Oral solid dosage contract manufacturing in Europe is growing at a decent pace, driven by a stringent regulatory environment, bolstered EMA, EU-GMP, demand growth for generics, and the growth of in-country CDMOs Recipharm, aenova. Government backing for pharma R&D, especially in Germany and France, provides a further fillip to capacity, thereby establishing Europe as the location of choice for world-class OSD contract manufacturing.

Asia-Pacific Emerges as the Fastest-Growing Oral Solid Dosage Contract Manufacturing Market (2026–2033)

The Asia Pacific region is projected to grow with the fastest CAGR of 6.41% over the forecast period 2026-2033, owing to its economic production, growing pharma infrastructure, and increasing generics demand. While countries including India, China have an abundance of cheap labor, regulatory-friendly plants (for example, WHO-GMP, USFDA certified), and growing investments over other countries. The up-trend of the use of innovation and minimally invasive practices in production in CDMOs in the region is at par with the developed world, as you see many growth factors favouring the CDMOs. The increasing healthcare needs of a massive population and favorable conditions contribute to the continued growth of outsourcing. All of these factors combined are driving the oral solid dosage contract manufacturing market growth in Asia-Pacific, which is therefore representing a key driver to global expansion.

Middle East & Africa Expands Its Footprint in the Oral Solid Dosage Contract Manufacturing Market

The Middle East & Africa have a substantially smaller but growing share of the oral solid dosage CMO market. Growth is fueled by investments in healthcare, growth in pharmaceutical infrastructure, and an increasing demand for low-cost generics. Nations including South Africa, the UAE, and Saudi Arabia are reforming their regulatory systems and enticing regional manufacturing partnerships, as a result, strengthening their presence in the global OSD outsourcing landscape.

Latin America Rises as a Growing Player in the Oral Solid Dosage Contract Manufacturing Market

The Latin American region is an up-and-coming contender within the oral solid dosage contract manufacturing market and has been on a constant rise, fueled by an increase in the generic medicines, healthcare accessibility, as well as government backing for home-grown manufacturers. Hub countries, including Brazil and Mexico, are positioned with the benefits of proximity to U.S. markets, cost advantage, and changing regulatory standards.

Competitive Landscape for the Oral Solid Dosage Contract Manufacturing Market:

Catalent, Inc.

Catalent, Inc. is a U.S.-based global leader in contract development and manufacturing, providing advanced oral solid dosage (OSD) solutions including tablets, capsules, modified-release formulations, and specialized technologies such as Zydis fast-dissolve systems. The company offers integrated services covering formulation development, clinical manufacturing, commercial-scale production, and packaging. Catalent plays a pivotal role in the OSD Contract Manufacturing Market by supporting pharmaceutical and biotech companies with scalable capacity, quality-focused manufacturing, and end-to-end supply chain capabilities that accelerate product commercialization.

• In 2025, Catalent expanded its commercial-scale OSD manufacturing capabilities by upgrading its U.S. and European facilities with enhanced high-potency and controlled-release production lines to support growing demand for complex formulations.

Lonza Group AG

Lonza Group AG is a Switzerland-based global CDMO specializing in high-quality pharmaceutical manufacturing, including extensive oral solid dosage services. The company provides formulation development, analytical testing, process optimization, granulation, tableting, encapsulation, and commercial-scale manufacturing. Lonza’s role in the OSD Contract Manufacturing Market is significant due to its expertise in complex OSD formulations, strong regulatory track record, and flexible production platforms that support both emerging biotech firms and major pharmaceutical companies.

• In 2025, Lonza strengthened its OSD portfolio by introducing an advanced formulation development platform designed to accelerate scale-up and improve bioavailability for poorly soluble compounds.

Thermo Fisher Scientific

Thermo Fisher Scientific is a U.S.-based global CDMO and life science leader offering comprehensive OSD manufacturing services across formulation development, clinical trial supply, commercial manufacturing, and packaging. The company operates a vast network of GMP-certified OSD facilities equipped for high-potency, controlled-release, and large-volume production. Thermo Fisher’s role in the OSD Contract Manufacturing Market is essential, providing fully integrated solutions that help pharmaceutical companies streamline development timelines and ensure consistent quality from concept to commercialization.

• In 2025, Thermo Fisher Scientific expanded its OSD manufacturing capacity with new high-potency tableting suites to meet rising demand for oncology and specialty medicines.

Recipharm AB

Recipharm AB is a Europe-based global contract manufacturer specializing in oral solid dosage development and large-scale commercial production. The company offers a wide range of OSD services, including formulation design, process development, tablet and capsule manufacturing, coating, quality testing, and packaging. Recipharm’s role in the OSD Contract Manufacturing Market is influential due to its flexible production model, multinational facility network, and ability to support both niche and high-volume pharmaceutical products with consistent regulatory compliance.

• In 2025, Recipharm expanded its OSD operations by upgrading its European plants with new continuous manufacturing technologies to improve throughput and enhance formulation precision.

Oral Solid Dosage Contract Manufacturing Market Key Players:

• Catalent, Inc.

• Lonza Group AG

• Thermo Fisher Scientific

• Recipharm AB

• Cambrex Corporation

• Piramal Pharma Solutions

• Almac Group

• Aenova Group

• Famar Health Care Services

• Strides Pharma Science Ltd.

• Corden Pharma International

• Siegfried Holding AG

• NextPharma

• Jubilant Pharmova Limited

• Boehringer Ingelheim International GmbH

• Fareva Holding SA

• Hetero Drugs Limited

• Pfizer CentreOne

• Evonik Industries AG

• Akums Drugs and Pharmaceuticals Limited